Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Urteste S.A. Logo
Develops non-invasive urine tests to detect cancers early by measuring enzyme activity.
Poland
URT
VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
Vera Therapeutics, Inc. Logo
Developing biologic therapies for serious immunological diseases, focusing on IgA Nephropathy.
United States of America
VERA
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea
308080
Viking Therapeutics, Inc. Logo
Biopharma developing novel therapies for metabolic and endocrine disorders like obesity and NASH.
United States of America
VKTX
Vinext S.p.A. Logo
Sustainable tech solutions for the wine, food, and beverage industry.
Italy
VNXT
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
Viridian Therapeutics, Inc.\DE Logo
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
United States of America
VRDN
VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.